KRAS and lung carcinoma: However, contrary to previous studies indicating that the combination of MAPK and CDK4/6 inhibitors induces RB protein-mediated cellular senescence and SASP activation, thereby enhancing NK cell immune surveillance and leading to the death of KRAS-mutant lung cancer cells [61].